Gilead Sciences (NASDAQ:GILD) can now market its tablet for HIV-1 infection - Genvoya - in Europe after the European Commission gave a green light.
Genvoya is for the treatment of adults and adolescents aged 12 years and older with body weight at least 35 kg infected with HIV-1.
It is the first TAF-based regimen to receive marketing authorization in the European Union (EU).
Norbert W. Bischofberger, Gilead’s executive vice president of research and development and chief scientific officer, said: “For more than 25 years, Gilead has continually worked to develop new treatments to improve the management of HIV.
“Genvoya, along with other investigational products in our TAF-based portfolio, have the potential to deliver long-term health benefits to people living with HIV across Europe and around the world.”
Anton Pozniak, HIV Service Director, Chelsea and Westminster Hospital, London, added: “With access to appropriate treatment, HIV patients today have the potential to live nearly as long as the general population.
"However, research shows they are at an increased risk of age- and treatment-related comorbidities, which means helping preserve long-term health should be a priority when making treatment decisions."
Gilead shares added 0.68% on Nasdaq.